Douglas M.  Hunt net worth and biography

Douglas Hunt Biography and Net Worth

Insider of Puma Biotechnology
Mr. Hunt joined Puma Biotechnology as Senior Vice President of Regulatory Affairs, Medical Writing and Project Management in January 2018. Mr. Hunt was Vice President of Regulatory Affairs and Quality Assurance at Armagen Inc, from April 2015 to December 2017, where he supported the continuing development of multiple products designed to cross the Blood Brain Barrier. He served as Vice President Global Regulatory Affairs for Baxter Healthcare from 2008 to 2015. During his tenure at Baxter he led a team responsible for gaining global approvals in various bleeding disorders, influenza and the treatment of various immune deficiencies. Notably, he supported the successful U.S. advisory Committee that supported the approval of HyQuvia. From March 2000 to July 2008, Mr. Hunt held various roles at Amgen, including Therapeutic Area lead in Inflammation and Oncology. During his tenure at Amgen, he supported the development and approval of Neulasta, Aranesp, Enbrel and NPlate. Prior to joining Amgen, Mr. Hunt worked for Quintiles, providing regulatory support to multiple development programs.

Mr. Hunt received a B.Sc from the University of Portsmouth (UK). He is a Fellow of the Regulatory Affairs Professionals Society.

What is Douglas M. Hunt's net worth?

The estimated net worth of Douglas M. Hunt is at least $364,819.20 as of November 2nd, 2022. Mr. Hunt owns 76,004 shares of Puma Biotechnology stock worth more than $364,819 as of March 18th. This net worth approximation does not reflect any other investments that Mr. Hunt may own. Additionally, Mr. Hunt receives an annual salary of $632,650.00 as Insider at Puma Biotechnology. Learn More about Douglas M. Hunt's net worth.

How old is Douglas M. Hunt?

Mr. Hunt is currently 59 years old. There are 4 older executives and no younger executives at Puma Biotechnology. The oldest executive at Puma Biotechnology is Dr. Alvin F. Wong Pharm.d., Chief Scientific Officer, who is 71 years old. Learn More on Douglas M. Hunt's age.

What is Douglas M. Hunt's salary?

As the Insider of Puma Biotechnology, Inc., Mr. Hunt earns $632,650.00 per year. There are 4 executives that earn more than Mr. Hunt. The highest earning executive at Puma Biotechnology is Mr. Alan H. Auerbach, Founder, Chairman, President, CEO & Secretary, who commands a salary of $1,740,000.00 per year. Learn More on Douglas M. Hunt's salary.

How do I contact Douglas M. Hunt?

The corporate mailing address for Mr. Hunt and other Puma Biotechnology executives is 10880 WILSHIRE BOULEVARD SUITE 2150, LOS ANGELES CA, 90024. Puma Biotechnology can also be reached via phone at (424) 248-6500 and via email at [email protected]. Learn More on Douglas M. Hunt's contact information.

Has Douglas M. Hunt been buying or selling shares of Puma Biotechnology?

Douglas M. Hunt has not been actively trading shares of Puma Biotechnology during the last ninety days. Most recently, Douglas M. Hunt sold 429 shares of the business's stock in a transaction on Wednesday, November 2nd. The shares were sold at an average price of $2.25, for a transaction totalling $965.25. Following the completion of the sale, the insider now directly owns 76,004 shares of the company's stock, valued at $171,009. Learn More on Douglas M. Hunt's trading history.

Who are Puma Biotechnology's active insiders?

Puma Biotechnology's insider roster includes Alan Auerbach (CEO), Douglas Hunt (Insider), Ann Miller (Director), Maximo Nougues (CFO), and Alvin Wong (Insider). Learn More on Puma Biotechnology's active insiders.

Are insiders buying or selling shares of Puma Biotechnology?

During the last year, insiders at the biopharmaceutical company sold shares 9 times. They sold a total of 199,396 shares worth more than $728,295.40. The most recent insider tranaction occured on January, 3rd when insider Alvin F Wong sold 7,733 shares worth more than $34,721.17. Insiders at Puma Biotechnology own 22.7% of the company. Learn More about insider trades at Puma Biotechnology.

Information on this page was last updated on 1/3/2024.

Douglas M. Hunt Insider Trading History at Puma Biotechnology

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/2/2022Sell429$2.25$965.2576,004View SEC Filing Icon  
10/3/2022Sell435$2.34$1,017.9076,433View SEC Filing Icon  
8/2/2022Sell429$2.89$1,239.8177,301View SEC Filing Icon  
7/5/2022Sell3,753$2.63$9,870.3977,730View SEC Filing Icon  
5/3/2022Sell438$2.31$1,011.7881,900View SEC Filing Icon  
3/2/2022Sell446$2.26$1,007.96View SEC Filing Icon  
2/2/2022Sell533$2.47$1,316.51View SEC Filing Icon  
1/3/2022Sell3,707$3.21$11,899.47View SEC Filing Icon  
11/2/2021Sell427$5.64$2,408.28View SEC Filing Icon  
10/4/2021Sell443$6.15$2,724.45View SEC Filing Icon  
9/2/2021Sell422$7.52$3,173.44View SEC Filing Icon  
8/2/2021Sell420$7.53$3,162.6066,523View SEC Filing Icon  
7/2/2021Sell1,016$9.15$9,296.4066,943View SEC Filing Icon  
6/2/2021Sell416$10.77$4,480.3267,959View SEC Filing Icon  
5/3/2021Sell417$9.91$4,132.4768,375View SEC Filing Icon  
4/5/2021Sell426$9.80$4,174.8068,792View SEC Filing Icon  
1/4/2021Sell6,463$10.23$66,116.4950,295View SEC Filing Icon  
2/27/2020Sell1,728$10.25$17,712.0052,830View SEC Filing Icon  
9/12/2019Sell1,711$11.42$19,539.6214,400View SEC Filing Icon  
See Full Table

Douglas M. Hunt Buying and Selling Activity at Puma Biotechnology

This chart shows Douglas M Hunt's buying and selling at Puma Biotechnology by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Puma Biotechnology Company Overview

Puma Biotechnology logo
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Read More

Today's Range

Now: $4.66
Low: $4.48
High: $5.00

50 Day Range

MA: $5.52
Low: $4.56
High: $7.40

2 Week Range

Now: $4.66
Low: $2.13
High: $7.73

Volume

1,294,484 shs

Average Volume

613,566 shs

Market Capitalization

$224.66 million

P/E Ratio

10.13

Dividend Yield

N/A

Beta

1.32